I initiate coverage on Merck & Co., Inc. with a Strong Buy rating and a $139 price target, driven by resilient execution and robust product depth. Merck is growing pharma sales and expanding ...

Despite mixed performance, Merck's stock has dropped 37% since mid-2024, but I maintain a buy rating due to long-term support and potential growth drivers. Merck's Q4 results beat expectations ...

Trodelvy + Keytruda improved progression-free survival over chemo + Keytruda in PD-L1+ metastatic TNBC. No new safety signals reported in ASCENT-04; overall survival trends will be tracked with ...

Winners of Merck Foundation "More Than a Mother" Media Recognition Awards 2024 Here are the winners from West African Countries in partnership with The First Lady of the Republic of The Gambia, H ...

Pharmaceutical companies including Pfizer, Merck, Johnson & Johnson and Bayer each gave $1 million to the inaugural committee for Trump and Vice President JD Vance, according to a filing with the ...

In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other stocks to buy according to Marjorie Taylor Greene. Marjorie Taylor Greene is one of the most ...

Patient centricity is a priority for Merck and its Executive Vice President and Head of EMEA Region for Merck Biopharma Global Commercial Operations, Chris Round, outlines what practical steps the ...

Germany’s Merck KGaA is paying $45 million upfront for rights to a potentially first-in-class drug for colorectal cancer (CRC) being developed by New York biotech Inspirna. The agreement gives ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Healthcare & Pharmaceuticalscategory· March 28, 2025 Merck plans to launch US subcutaneous version of Keytruda on October 1 Merck & Co said on Thursday that it plans to launch a subcutaneously ...